By Jason Napodano, CFA
On May 27, 2012, Cipher Pharmaceuticals (DND.TO) (OTC:CPHMF) announced it had received U.S. FDA approval of Absorica, the company's novel, patented brand formulation of the acne medication isotretinoin, for the treatment of severe recalcitrant nodular acne. On November 26, 2012, Cipher's U.S. commercial partner for the drug, Ranbaxy Laboratories, Inc. (OTC:RBXZF) officially launched the product. We remind investors that approval triggered two milestone payments from Ranbaxy to Cipher totaling $9.0 million, of which Cipher is to retain 50% after paying sub-milestones to Galephar Pharmaceuticals of Puerto Rico, which will handle the manufacturing of the product. This is good news for anyone that has been keeping an eye on Ranbaxy's...
Only subscribers can access this article, which is part of the PRO research library covering 3,768 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: